Cancer Cell Targeting Articles & Analysis
29 news found
Combined with nanotechnology, "smart" drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. ...
Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. Such APIs come in a wide range of types: chemotherapeutic, targeted, immunotherapeutic, hormone therapeutic. The APIs in chemotherapy work by interfering with the cell division mechanism to suppress ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell ...
The most common and most lethal of these cancerous tumors are glioblastoma (GBM). What is Glioblastoma? Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. ...
Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed on colorectal cancer and other cancers. ...
CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. ...
Logic Gated FLT3 OR CD33 NOT EMCN CAR-NK Cell Therapy (SENTI-202) for Precise Targeting of AML, Garrison et al. ...
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, SuppresSTEM which included Crown ...
Highlights Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions Four presentations describe preclinical data from Carina’s LGR5-targeted CAR-T cell program, one poster will describe preclinical data from Carina’s ADAM-10 CAR-T program With its LGR5 CAR-T, Carina ...
ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. ...
ByScancell
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa ...
It is a potent anticancer drug that targets cancer cells at a specific site, and is considered to be an important means of disease treatment in the future. ...
It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer. Proton therapy targets cancer cells more precisely than traditional x-ray photon therapy, and results in less damage to surrounding healthy tissue and sensitive organs ...
GammaTiles, postage stamp-sized 3D collagen tiles embedded with radiation seeds, directly target cancer cells at the tumor cavity site. They are implanted by the surgeon and deliver ninety percent of the radiation dose in 33 days. ...
It does this by delivering cancer-associated proteins — known as MAGE-A3 and NY-ESO-1 antigens — to antigen presenting cells (dendritic cells), causing the immune system to produce cytotoxic T cells which are able to target and kill cancer cells expressing these ...
Lentiviruses are widely used as a tool to deliver genes of interest to cells. In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s T cells (immune cells), which turn the T cells into cancer-killing CAR-T cells targeting LGR5, a ...
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. ...
“Through this collaboration, our platform will form the basis of a personalized allogeneic cell therapy vision, where any patient can receive a T-cell product for their cancer; a significant step towards our goal of making cell therapies both curative and ...
“At Carina Biotech, we are focused on our goal of creating a future that defeats cancer. The LGR5 CAR-T cell for advanced colorectal cancer is a great place to start, given this cancer’s very poor prognosis and rising incidence, particularly in younger people. ...
Jean-Christophe Hyvert, President, Biologics and Cell & Gene Divisions, Lonza, commented: “This expanded customer relationship truly exemplifies our value and capabilities as a strategic partner on the path to commercialization. ...